单唾液酸四己糖神经节苷脂钠注射液治疗重型颅脑损伤的疗效观察

目的观察单唾液酸四己糖神经节苷脂钠注射液对重型颅脑损伤患者血浆肌酸激酶同工酶BB（CreatinekinaseBB,CK-BB）的动态变化以及临床疗效。方法将60例重型颅脑损伤患者（GCS≤8分）分成两组,观察组30例在常规治疗的基础上加用单唾液酸四己糖神经节苷脂钠注射液治疗,对照组30例采用常规治疗。观察患者血浆CK-BB变化,并两组于伤后6个月按GOS预后评分评定预后,同时比较两组患者的意识好转率。结果观察组患者血浆CK-BB明显低于对照组。观察组恢复良好率（17/30）与对照组（8/30）比较,差异有统计学意义（P〈0.05）。观察组治疗后1个月清醒23例,而对照组l3例,两组清醒率比较,差异有统计学意义（P〈0.01）。两组清醒时间比较,观察组为（14.56±6.56）天,对照组为（20.85±10.92）天。结论单唾液酸四己糖神经节苷脂钠注射液能有效降低重型颅脑损伤患者血浆CK-BB的水平,并且不仅能加速重型颅脑损伤患者清醒,还能促进预后,提高生活质量。单唾液酸四己糖神经节苷脂钠注射液是治疗重型颅脑损伤安全有效的药物,可以广泛地应用于临床。

Clinical study of monosialotetrahexosylganlioside sodium injection in treatment of severe traumatic brain injury

Objective To study the influence of monosialotetrahexosylganlioside sodium injection(GM-1) on the level of plasma creatine kinase BB(CK-BB) and the clinical effect for severe traumatic brain injury.Methods 60 patients with severe traumatic brain injury(GSC≤8) were divided into two groups:edaravone group(n=30) treated with GM-1 besides the routine treatment and control group(n=30) treated only with the conventional therapy.Plasma CK-BB of patients was observed.The clinical prognosis of the patients(GOS scores and the consciousness-improved rate) was evaluated six months after being injured.Results Plasma CK-BB in GM-1 group was significantly lower than that in control group.The rate of good recovery was 17/30 in the GM-1 group,significantly higher than 8/30 of the control group(P<0.05).The consciousness of 32 cases after one month in the GM-1 group was significantly improved but only 18 cases in control group(P<0.01).The revival time(14.56±6.56 days) in GM-1 group was significantly shorter than that(20.85±10.92 days) in control group.Conclusion GM-1 can decrease the level of plasma CK-BB in the patients with severe traumatic brain injury,and promote revival from coma and improve life quality in patients with severe traumatic brain injury.GM-1 is a good choice of treatment for severe traumatic brain injury.It can be clinically applicatied extensively.